Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Research

Targeted Screening for Chronic Q Fever, the Netherlands

Daphne F.M. ReukersComments to Author , Pieter T. de Boer, Alfons O. Loohuis, Peter C. Wever, Chantal P. Bleeker-Rovers, Arianne B. van Gageldonk-Lafeber, Wim van der Hoek, and Aura Timen
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.F.M. Reukers, P.T. de Boer, A.B. van Gageldonk-Lafeber, W. van der Hoek, A. Timen); Q-Support Foundation, ’s-Hertogenbosch, the Netherlands (A.O. Loohuis); Radboud University Medical Center, Nijmegen, the Netherlands (A.O. Loohuis, C.P. Bleeker-Rovers); Jeroen Bosch Hospital, ’s-Hertogenbosch (P.C. Wever); Vrije Universiteit, Amsterdam (A. Timen)

Main Article

Table 3

Characteristics of all study participants, patients with a previous Coxiella burnetii infection, and patients suspected of having chronic Q fever, the Netherlands*

Characteristic
 All participants, n = 1,642
 Previous infection, IgG II titer >1:64, n = 289
 Suspected of having chronic Q fever, IgG I titer >1:512, n = 9
Mean age, y 63 64 63
Age >60 y, % of total 66 65 78
Male sex, % of total
 49
 59
 67
Risk factor, no.†
Heart valve 460 103 0
Vascular 202 50 4
Other cardiovascular 105 20 1
Immunocompromised by illness 419 57 1
Immunocompromised by medication 445 59 3
Missing 135 18 0

*Corresponding International Classification of Primary Care codes for risk factor: heart valve, K83; vascular, K99.01; other cardiovascular, K73 and K71; immunocompromised by illness; B73, B74, B90, and D94; immunocompromised by medication, L04A. †Some participants had multiple risk factors.

Main Article

Page created: May 06, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external